Law firm investigates enGene Therapeutics after stock drops on disappointing trial results

Johnson Fistel, PLLP is investigating potential claims for investors of enGene Therapeutics following the company's disclosure of less favorable results from its Phase 2 trial for a bladder cancer treatment. The updated data showed lower complete response rates and durability than expected, causing enGene's stock price to fall sharply. The investigation will assess whether enGene's executives complied with federal securities laws. Investors who suffered losses are encouraged to contact Johnson Fistel for possible recovery options.